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Introduction
Excessive daytime sleepiness (EDS) is a common
symptom, which affects up to 5% of the population.
The differential diagnosis of EDS includes sleep
deprivation, sleep-associated breathing disorders, and
such neurological disorders as narcolepsy, idiopathic
hypersomnia, and posttraumatic hypersomnia.
The pathophysiology of EDS is unknown in most
of these conditions. No neurochemical measure of
EDS is known. In narcolepsy, an abnormal hypocretin
transmission with low cerebrospinal fluid (CSF) levels
of hypocretin-1 (orexin A) was recently discovered
[1]. Since hypocretin deficiency (1) is usually detected
only when cataplexy is present and (2) is rare in non-
narcoleptic patients with EDS, other neurochemical
pathways are probably implicated in EDS [2, 3].
The enzyme lipocalin-type prostaglandin D syn-
thase (L-PGDS; also known as b-trace) is involved
in sleep-wake regulation in rodents, primates and
humans [4]. L-PGDS is synthesized in the brain and
secreted into the CSF, where it is the sole source of
prostaglandin D2 (PGD2), which has potent som-
nogenic effects. In normal conditions, a 32:1
CSF-serum concentration gradient has been found
for L-PGDS [4]. In humans, serum L-PGDS con-
centrations show a circadian pattern and are re-
duced during sleep deprivation; furthermore, CSF
PGD2 is increased in African sleeping sickness [5,
6].
We hypothesized that changes in CSF L-PGDS
levels may be found in patients with EDS secondary to
narcolepsy, other neurological disorders, and chronic
sleep deprivation.
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j Abstract Lipocalin-type prosta-
glandin D synthase (L-PGDS) is a
brain enzyme, which produces
prostaglandin D2, a substance with
endogenous somnogenic effects.
Using a standardized protocol for
immunonephelometric determi-
nation of cerebrospinal fluid
(CSF) L-PGDS levels, we show
that CSF L-PGDS levels are
significantly lower in 34 patients
with excessive daytime sleepiness
when compared with levels in 22
healthy controls. Thus, L-PGDS
may represent the first neuro-
chemical measure of excessive
daytime sleepiness.
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Subjects and methods
j Subjects
We enrolled 14 patients with narcolepsy with cataplexy (EDS-NC;
seven women, seven men, mean age 36 years, range 19–63, SD 14),
16 patients with EDS secondary to other (mainly) neurological
disorders (EDS-N; five women, 11 men, mean age 37 years, range
20–67, SD 13), four patients with EDS due to chronic sleep depri-
vation (CSD; four men, mean age 40 years, range 30–66, SD 17), and
22 controls without sleep-wake disturbances or other neurological
disorders (11 women, 11 men, mean age 34 years, range 17–60, SD
13) in this study, which was performed according to local ethical
committee standards. All subjects gave informed consent for the
study.
Sleep disorders were diagnosed clinically and using sleep
studies, according to international criteria [7]. Narcolepsy with
cataplexy was diagnosed by sleep questionnaires and additional
investigations (including hypocretin-1 determination in CSF, HLA
phenotyping in serum, polysomnography, multiple sleep latency
tests). Diagnoses in EDS-N included idiopathic hypersomnia (n=4),
periodic hypersomnia (n=1), narcolepsy without cataplexy (n=2),
posttraumatic hypersomnia (n=4), postischemic/postinfectious
hypersomnia (n=1/1), familial hypersomnia of unknown origin
(n=2), and EDS with Parkinson’s disease (n=1). In CSD patients, no
sleep-wake or neurological disorders were identified. None of our
patients or controls had normal pressure hydrocephalus, spinal
canal stenosis, posttraumatic or postinfectious leptomeningeal
dysfunctions, or any significant cardiovascular, neurological or
renal disorder known to influence L-PGDS levels.
j Methods
All patients were medication-free; a drug washout of 14 days had
been performed prior to the examinations. We assessed the
severity of EDS subjectively by the Epworth sleepiness scale, and
objectively by the multiple sleep latency test (MSLT). L-PGDS
levels were determined in the CSF with albumin as reference
protein by an immunonephelometric assay (Dade-Behring GmbH,
Marburg, Germany) on an automated analyzer [8]. Lumbar CSF
was collected only between 10 am and 1 pm to minimize the
influence of circadian variation of L-PGDS levels. Thereafter, CSF
was immediately frozen at )80C for storage, and crude CSF was
not defrosted until determination of L-PGDS. Measurements of
all samples were performed in the same assay to prevent influ-
ence of inter-assay variability, and have been repeated in a
second and third assay. CSF hypocretin-1 determinations were
performed by a commercially available radioimmuno assay
(Phoenix Pharmaceuticals, Belmont, CA, USA; determination
procedure: as described before) [9]. Furthermore, we determined
CSF/serum albumin ratio to assess the integrity of the blood-
brain barrier [10].
Statistical analyses were performed by Student’s t-tests, ANO-
VA, and Pearson correlation tests. Significance was declared at
p£0.05 level.
Results
The results are summarized in figure 1 and table 1.
Mean Epworth Sleepiness Scale scores were 15.9 (SD
3.6) in EDS-NC, 13.8 (SD 5.5) in EDS-N, and 14.0 (SD
2.0) in CSD. Mean sleep latencies on MSLT were 2.3
minutes (SD 1.7) in EDS-NC, 4.3 minutes (SD 2.6) in
EDS-N, and 3.8 minutes (SD 0.8) in CSD. CSF
hypocretin-1 levels were undetectable/low in 11 of 14
EDS-NC patients, and normal in all other subjects.
L-PGDS levels in EDS-NC (mean 14.7 mg/L, range
7.0–19.0, SD 3.8, p=0.002), EDS-N (mean 16.6 mg/L,
range 11.0–24.8, SD 3.8, p=0.011), and CSD (mean
13.8 mg/L, range 12.9–15.9, SD 1.4, p=0.042) were
significantly lower than in controls (mean 21.3 mg/L,
range 11.7–36.8, SD 6.8). These results have been
confirmed by repeated determinations with a second
and third assay. Mean levels did not differ signifi-
cantly between EDS-NC, EDS-N and CSD patients. In
the control group, CSF L-PGDS levels were higher in
men (mean 22.7 mg/L) than in women (mean 19.8
mg/L), but this finding was not significant (p=0.33).
Within the narrow time interval of CSF withdrawal,
there was no association between L-PGDS levels and
the time of lumbar puncture.
There were no correlations between CSF L-PGDS
levels and age, Epworth Sleepiness Scale score, or
mean sleep latency on MSLT. However, mean sleep
latencies and L-PGDS levels were lower in EDS with
undetectable CSF hypocretin-1 levels (n=9; mean
sleep latency: 1.7 minutes, SD 1.0; mean L-PGDS 13.1
mg/L, SD 3.3) than in patients with detectable levels
(n=5; mean sleep latency: 4.2 minutes, SD 2.5; mean
L-PGDS 16.9 mg/L, SD 3.6). CSF hypocretin-1 levels
correlated positively with L-PGDS levels (n=56,
r=0.43, p=0.001). Mean CSF/serum albumin ratio in
EDS patients (EDS-NC and EDS-N) was 4.6 (SD=1.3,
range 2.1–6.8), compared with the mean of 4.3
(SD=1.1, range 2.2–5.9) in the controls (p=0.62).
Mean CSF/serum albumin ratios did not correlate
with CSF L-PGDS levels.
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Fig. 1 L-PGDS levels in 34 EDS patients and 22 controls. L-PGDS levels
(b-trace, in mg/L) in 14 patients with narcolepsy-cataplexy (EDS-NC), 16
patients with excessive daytime sleepiness (EDS) due to other neurological
disorders (EDS-N), 4 patients with EDS due to chronic sleep deprivation (CSD),
and 22 controls (CO). Horizontal lines indicate mean levels
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Discussion
Our data demonstrate that L-PGDS activity – as re-
flected by lumbar CSF levels - is decreased in EDS
secondary to narcolepsy, other neurological disor-
ders, and chronic sleep deprivation. Considering the
recent finding of decreased serum L-PGDS levels
during total sleep deprivation, [5] these observations
suggest a reduction (downregulation?) of the prosta-
glandin D system activity in the brain in the presence
of EDS and increased sleep propensity. The discrep-
ancy between our finding of low CSF L-PGDS levels
(which has been replicated in repeated measure-
ments) and the recent report of increased serum levels
in narcoleptic patients cannot be explained yet [11].
The finding of discrepant serum and CSF L-PGDS
concentrations was recently found to be useful to
detect CSF leaks [12]. Similarly, earlier reports found
that CSF L-PGDS levels can be used in conjunction
with CSF/serum albumin ratio to distinguish between
different neurological pathologies associated with CSF
protein increase and blood-brain barrier dysfunctions
[13]. Due to our finding of similar CSF/serum albu-
min ratios in EDS patients and in controls, however,
we assume that alterations in the blood-brain barrier
function may not be the primary cause for our find-
ing. Thus, further studies to determine simulta-
neously L-PGDS in serum and CSF are required.
The large overlap in CSF L-PGDS levels between
EDS patients and controls indicates that this test may
not serve as a diagnostic tool for EDS in clinical
practice.
Conclusion
This study does not allow to elucidate the role of
L-PGDS in the pathophysiology of EDS. Considering
the neurochemical complexity of sleep-wake regu-
lation and the heterogeneity of disorders included
in our study, it is likely that the link between
decreased L-PGDS levels and EDS is complex.
Rather we postulate a decrease of L-PGDS activity
reflecting the interaction, recently shown experi-
mentally, between the prostaglandin D system,
arousal-promoting monoaminergic neurons in the
brainstem, and sleep-active neurons in the preoptic
area [14,15].
Table 1 Patients’ characteristics EDS-NC: patients with narcolepsy-cataplexy, EDS-N patients with excessive daytime sleepiness due to other neurological disorders,
CSD: patients with chronic sleep deprivation, CO: controls. Hcrt: hypocretin-1 levels in pg/ml. ESS=Epworth sleepiness scale. n.a.=not available
Diagnosis n Sex Age (years) ESS MSL (min) L-PGDS (mg/L) Hcrt (pg/mL)
m:f mean range SD mean SD mean SD mean range SD mean SD
EDS-NC 14 7:7 36 19–63 14 15.9 3.6 2.3 1.7 14.7 7.0–19.0 3.8 125 230
EDS-N 16 11:5 37 20–67 13 13.8 5.5 4.3 2.6 16.6 11.0–24.8 3.8 470 139
CSD 4 4:0 40 30–66 17 14.0 2.0 3.8 0.8 13.8 12.9–15.9 1.4 495 113
CO 22 11:11 34 17–60 13 n.a. n.a. n.a. n.a. 21.3 11.7–36.8 6.8 526 102
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